April 24th 2024
In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
PET Imaging Study Suggests Possible Chemotherapy-Free Pathway for Treating Early Breast Cancer
April 5th 2024Utilizing PET imaging to assess pathologic complete response to the combination of trastuzumab and pertuzumab for patients with HER2-positive breast cancer, researchers noted a 94.8 percent rate of invasive disease-free survival at three years.
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
Study: PET/MRI May Prevent Up to 83 Percent of Unnecessary Biopsies in Men with PI-RADS 3 Lesions
March 15th 2024For men with PI-RADS 3 lesions, PRIMARY scores of 4-5 with PET/MRI had a sensitivity rate of 87.5 percent for clinically significant prostate cancer, according to newly published research.
ECR Study Examines Key Predictive Factors for Metastasis in Patients with High-Risk Prostate Cancer
February 28th 2024Sixty-five percent of patients with newly diagnosed high-risk prostate cancer may have extraprostatic extension on MRI, and PSMA PET/CT findings suggest those with Gleason scores of eight or higher have more than double the risk of metastasis, according to a new study presented at the European Congress of Radiology (ECR).
Assessing the Potential of Positron Emission Mammography: An Interview with Vivianne Freitas, MD
February 12th 2024In a recent interview, Vivianne Freitas, M.D., discussed new research findings on positron emission mammography (PEM), pertinent benefits of the technology and its potential as a viable alternative in the future to conventional imaging techniques for breast cancer screening.
Can Positron Emission Mammography Have an Impact in Diagnosing Invasive Breast Cancer?
February 9th 2024Findings from a new pilot study showed that low-dose positron emission mammography (PEM) detected 96 percent of malignant index lesions and had a 46 percent lower false-positive rate in comparison to breast MRI.
What Post-Void MRIs May Reveal About Midline Radiotracer Activity on PSMA PET/CT
January 26th 2024Patients with localized high-risk prostate cancer and midline radiotracer activity in the prostate had over double the incidence of urethral hyperintensity on T2W MRI, according to research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU).
Study: PSMA PET/CT Identifies 18 Percent More Metastatic Renal Cancers than Conventional Imaging
January 15th 2024In addition to detecting more than double the number of distant lymph nodes and distant lesions in comparison to conventional imaging with computed tomography (CT), PSMA PET/CT reportedly changed management for 32 percent of patients.
Patent Battle Brewing Between Novartis, Lantheus Over Generic Lutathera Radioligand Therapy
January 12th 2024The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.